Fig. 6

Hypoglycemic effect of oligomeric DOCA-G1As in db/db mice. A IPGTT after treatment with control (saline, oral, n = 4), exenatide (5 µg/kg, subcutaneous, n = 4), bD-G1A (50 μg/kg, oral, n = 4), and tD-G1A (50 μg/kg, oral, n = 4) following glucose (2 g/kg) injection. Data are presented as mean ± standard deviation. ^**p < 0.01 compared with the control. B Time course of changes in blood glucose levels of db/db mice displaying a high fasting glucose level after treatment with exenatide (5 µg/kg, subcutaneous, n = 4), GLP-1A-Cys (20 μg/kg, oral, n = 4), bD-G1A (20 μg/kg, oral, n = 4), and tD-G1A (20 μg/kg, oral, n = 4). Data are presented as means ± standard deviations. ^*p < 0.05, ^**p < 0.01, and ^***p < 0.001 compared with exenatide. ^###p < 0.001 compared with GLP-1A-Cys